5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-06, Vol.41 (S2), p.231-233
Main Authors: Ahn, I. E., Brander, D. M., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H. A., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C. A., Armand, P., Ng, S., Crombie, J., Fisher, D. C., LaCasce, A. S., Arnason, J., Hochberg, E. P., Takvorian, R. W., Abramson, J. S., Brown, J. R., Davids, M. S.
Format: Article
Language:English
Subjects:
Chronic lymphocytic leukemia
Cyclophosphamide
Fludarabine
Rituximab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3163_152